MedVellum
MedVellum
Back to Library
Neurology
Geriatrics

Parkinson's Disease

High EvidenceUpdated: 2025-12-24

On This Page

Red Flags

  • Falls early in disease (PSP?)
  • Poor Levodopa response (MSA?)
  • Rapid progression
  • Symmetrical onset
Overview

Parkinson's Disease

1. Clinical Overview

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the classic motor features known as the TRAP tetrad: Tremor, Rigidity, Akinesia/Bradykinesia, and Postural instability. It is the second most common neurodegenerative disease after Alzheimer's, affecting approximately 1% of people over 60 years. The disease also causes significant non-motor symptoms including anosmia, depression, constipation, and REM sleep behavior disorder. While there is no cure, levodopa remains the most effective treatment, though long-term use leads to motor complications including dyskinesias and motor fluctuations.

Clinical Pearls:

  • Second most common neurodegenerative disease (after Alzheimer's)
  • Asymmetric onset is characteristic (distinguishes from atypical parkinsonism)
  • Resting tremor (4-6 Hz) is the most recognizable feature but not always present
  • Non-motor symptoms often precede motor symptoms by years
  • Levodopa is most effective treatment but causes dyskinesias after 5-10 years

Red Flags (Suggesting Atypical Parkinsonism):

  • Falls early in disease: Suggests progressive supranuclear palsy (PSP)
  • Poor levodopa response: Suggests multiple system atrophy (MSA) or PSP
  • Symmetrical onset: Atypical for PD
  • Rapid progression: Suggests atypical parkinsonism
  • Early cognitive decline: Suggests dementia with Lewy bodies
  • Early autonomic failure: Suggests MSA
2. Epidemiology

PD is a common neurodegenerative disorder with increasing prevalence with age. Understanding epidemiology aids in diagnosis and resource planning.

Key Statistics:

  • Prevalence: 1% of population over 60 years, 2-3% over 80 years
  • Incidence: 10-20 per 100,000 per year
  • Age of onset: Peak 60-70 years, rare before 40
  • Gender: Slight male predominance (1.5:1)
  • Global burden: 6.1 million people affected worldwide (2016)

Geographic Variation:

  • Higher in industrialized countries: Possibly due to environmental factors
  • Lower in Africa and Asia: May reflect underdiagnosis
  • Urban vs rural: Slightly higher in urban areas

Risk Factors:

  • Age: Strongest risk factor, risk increases exponentially with age
  • Gender: Male sex increases risk
  • Genetics: 10-15% have family history, multiple genes identified
  • Environmental: Pesticide exposure, head trauma (controversial)

Mortality and Morbidity:

  • Life expectancy: Reduced by 1-2 years
  • Disability: Progressive, significant impact on quality of life
  • Falls: Common, cause of significant morbidity
  • Cognitive decline: 40-80% develop dementia over time
3. Pathophysiology

PD results from progressive loss of dopaminergic neurons in the substantia nigra, leading to dopamine deficiency in the striatum. Multiple pathogenic mechanisms contribute to neuronal death.

Pathophysiology Steps:

  1. Neuronal Loss: Progressive degeneration of dopaminergic neurons in substantia nigra pars compacta, with 50-70% loss before symptoms appear. Loss occurs over years to decades

  2. Alpha-Synuclein Aggregation: Misfolded alpha-synuclein protein aggregates form Lewy bodies and Lewy neurites. These aggregates spread through the brain in a prion-like manner, following Braak staging

  3. Dopamine Depletion: Loss of dopaminergic neurons reduces dopamine in the striatum (caudate and putamen), disrupting the direct and indirect pathways of the basal ganglia motor circuit

  4. Basal Ganglia Circuit Dysfunction: Reduced dopamine causes overactivity of the indirect pathway (inhibitory) and underactivity of the direct pathway (excitatory), leading to increased output from the globus pallidus interna and substantia nigra pars reticulata

  5. Thalamic Inhibition: Increased inhibitory output from basal ganglia suppresses thalamocortical projections, reducing cortical activation and causing bradykinesia, rigidity, and tremor

  6. Oxidative Stress: Mitochondrial dysfunction, particularly complex I deficiency, increases reactive oxygen species, contributing to neuronal death

  7. Neuroinflammation: Activated microglia and inflammatory cytokines contribute to ongoing neuronal damage and disease progression

4. Risk Factors

Non-Modifiable Risk Factors:

  • Age: Strongest risk factor, risk increases exponentially after age 60
  • Gender: Male sex (1.5:1 ratio)
  • Genetics: 10-15% have family history, multiple genes identified (SNCA, LRRK2, GBA, PARKIN)
  • Ethnicity: Slight variations, but affects all populations

Modifiable Risk Factors:

  • Pesticide exposure: Increased risk with organochlorine pesticides
  • Head trauma: Controversial, some studies suggest increased risk
  • Rural living: Slightly increased risk, possibly due to pesticide exposure
  • Well water: Possible association

Genetic Factors:

  • SNCA (alpha-synuclein): First gene identified, rare but highly penetrant
  • LRRK2: Most common genetic cause, 1-2% of sporadic PD
  • GBA: Glucocerebrosidase mutations, 5-10% of PD
  • PARKIN, PINK1, DJ-1: Early-onset PD, autosomal recessive
  • >20 genes identified: Most are rare

Protective Factors:

  • Caffeine: Moderate coffee consumption reduces risk
  • Smoking: Inverse association (not recommended due to other risks)
  • Exercise: Regular physical activity may reduce risk
  • NSAIDs: Some studies suggest protective effect
5. Clinical Presentation

PD presents with both motor and non-motor symptoms. Motor symptoms typically begin asymmetrically and progress. Non-motor symptoms often precede motor symptoms by years.

Motor Symptoms (TRAP):

Tremor:

Rigidity:

Akinesia/Bradykinesia:

Postural Instability:

Non-Motor Symptoms:

Early (May Precede Motor Symptoms):

Later:

Type
Resting tremor, 4-6 Hz frequency
Character
Pill-rolling, most prominent at rest
Distribution
Asymmetric, typically starts in one hand
Progression
Spreads to other limbs, may involve jaw, lips
Suppression
Reduces with action, increases with stress
6. Examination

Comprehensive neurological examination identifies cardinal features and assesses disease severity. Serial examinations track progression and response to treatment.

Motor Examination:

Tremor:

  • Observation: Resting tremor in hands, may be subtle
  • Activation: Ask patient to hold arms outstretched, tremor may re-emerge
  • Distribution: Asymmetric, may involve legs, jaw
  • Frequency: 4-6 Hz, regular

Rigidity:

  • Passive movement: Increased resistance in all directions
  • Cogwheel: Ratcheting quality if tremor present
  • Distribution: Asymmetric, check neck, arms, legs
  • Activation: Contralateral movement increases rigidity (Froment's maneuver)

Bradykinesia:

  • Finger taps: Reduced amplitude, slowing, arrests
  • Hand movements: Opening/closing, reduced amplitude
  • Foot taps: Slowing, reduced amplitude
  • Rapid alternating movements: Slowing, irregular rhythm

Posture and Gait:

  • Posture: Stooped, may have retropulsion
  • Gait: Shuffling, reduced arm swing, small steps
  • Turning: En bloc, multiple steps
  • Freezing: Episodes of inability to step
  • Pull test: Test postural stability (pull backward, assess recovery)

Other Motor Features:

  • Facial expression: Hypomimia (masked facies)
  • Speech: Hypophonic, monotone, may have dysarthria
  • Eye movements: Saccades may be slow, pursuit may be saccadic
  • Micrographia: Small handwriting

Non-Motor Assessment:

  • Cognition: Screen with MoCA or MMSE
  • Mood: Screen for depression and anxiety
  • Autonomic: Blood pressure lying and standing
  • Smell: Test with smell identification test if available

Hoehn and Yahr Staging:

StageDescription
1Unilateral symptoms only
1.5Unilateral + axial involvement
2Bilateral symptoms, no balance impairment
2.5Mild bilateral disease, recovery on pull test
3Mild to moderate bilateral disease, some postural instability, physically independent
4Severe disability, still able to walk/stand unassisted
5Wheelchair bound or bedridden unless aided
7. Investigations

Diagnosis is primarily clinical. Investigations are used to exclude other causes and assess for complications. No definitive diagnostic test exists.

Clinical Diagnosis:

  • UK Brain Bank Criteria: Requires bradykinesia plus at least one of: rigidity, resting tremor, or postural instability
  • Supportive features: Asymmetric onset, progressive course, excellent levodopa response
  • Exclusion criteria: Features suggesting atypical parkinsonism

Imaging:

DaTscan (Ioflupane SPECT):

  • Purpose: Assesses dopamine transporter in striatum
  • Finding: Reduced uptake in PD (asymmetric)
  • Use: Distinguishes PD from essential tremor, drug-induced parkinsonism
  • Limitations: Cannot distinguish PD from atypical parkinsonism

MRI Brain:

  • Purpose: Excludes structural causes, assesses for atypical features
  • PD: Usually normal early, may show mild atrophy later
  • Atypical: May show specific patterns (hummingbird sign in PSP, hot cross bun in MSA)

PET/SPECT:

  • FDOPA PET: Assesses dopaminergic function
  • Not routinely used: Expensive, mainly research

Other Investigations:

  • Blood tests: Exclude other causes (thyroid, B12, syphilis)
  • Genetic testing: If family history or early onset
  • Autonomic testing: If significant autonomic symptoms
  • Sleep study: If REM sleep behavior disorder

Levodopa Challenge Test:

  • Purpose: Assesses response to levodopa
  • Method: Administer levodopa, assess motor function before and after
  • Response: >30% improvement in UPDRS suggests PD
  • Use: Helps confirm diagnosis, guides treatment

Differential Diagnosis Considerations:

ConditionDistinguishing Features
Essential tremorAction tremor, no bradykinesia, family history
Drug-induced parkinsonismHistory of dopamine-blocking drugs, symmetric
Progressive supranuclear palsyEarly falls, vertical gaze palsy, poor levodopa response
Multiple system atrophyEarly autonomic failure, cerebellar signs, poor levodopa response
Dementia with Lewy bodiesEarly cognitive decline, visual hallucinations, fluctuations
Vascular parkinsonismStepwise progression, lower body predominance, vascular risk factors
8. Management

Management is symptomatic and multidisciplinary. Levodopa is most effective but causes long-term complications. Treatment is individualized based on age, symptoms, and disease stage.

PARKINSON'S DISEASE MANAGEMENT ALGORITHM
========================================

Patient diagnosed with PD
                |
                v
        Assess Disease Stage and Symptoms
                |
                +-------------------+-------------------+
                |                   |                   |
        EARLY STAGE            MODERATE STAGE      ADVANCED STAGE
        (H&Y 1-2)              (H&Y 2.5-3)         (H&Y 4-5)
                |                   |                   |
        Consider Treatment    Levodopa or         Optimize Levodopa
        Options:              Combination         - Increase frequency
        - MAO-B inhibitors    - Add COMT          - Add COMT inhibitor
        - Dopamine agonists    inhibitor          - Consider DBS
        - Levodopa (if older) - Add MAO-B         - Apomorphine
        - Amantadine          inhibitor           - LCIG
                              - Consider DBS

                    LEVODOPA MANAGEMENT
                        |
                        +-------------------+-------------------+
                        |                   |                   |
                Initial Dosing          Motor Complications    Optimization
                        |                   |                   |
            - Start low (50-100mg)  - Dyskinesias:         - Increase frequency
              tds, increase         Reduce dose, add       - Add COMT inhibitor
              gradually             amantadine             - Consider DBS
            - With carbidopa        - Wearing off:         - LCIG if severe
              (25/100 or 50/200)    Increase frequency,    fluctuations
            - Avoid high protein      add COMT inhibitor
              meals                 - ON-OFF: Consider
                                      continuous delivery

                    NON-MOTOR SYMPTOM MANAGEMENT
                        |
                        +-------------------+-------------------+
                        |                   |                   |
                Depression/Anxiety    Cognitive Impairment  Autonomic
                        |                   |                   |
            - SSRI/SNRI            - Cholinesterase        - Orthostatic
            - Consider             inhibitors (donepezil)  hypotension:
              pramipexole          - Memantine if severe     Fludrocortisone,
              (antidepressant                              midodrine
              effect)                                      - Urinary:
                                                              Anticholinergics
                                                              - Constipation:
                                                                Laxatives

                    SURGICAL OPTIONS
                        |
                        v
            Deep Brain Stimulation (DBS)
            - Subthalamic nucleus (STN) or
              Globus pallidus interna (GPi)
            - Indications: Motor fluctuations,
              dyskinesias, tremor
            - Best candidates: less than 70 years,
              good cognition, levodopa responsive

Pharmacological Management:

Levodopa (with Carbidopa or Benserazide):

  • Most effective: For motor symptoms
  • Dosing: Start 50-100mg levodopa tds, increase gradually
  • Formulations: Immediate release, controlled release, dispersible
  • Side effects: Nausea, orthostatic hypotension, dyskinesias (long-term)
  • Motor complications: Dyskinesias, wearing off, ON-OFF fluctuations after 5-10 years

Dopamine Agonists:

  • Options: Ropinirole, pramipexole, rotigotine patch
  • Use: Monotherapy in young patients, adjunct to levodopa
  • Benefits: Less dyskinesias than levodopa, longer half-life
  • Side effects: Nausea, somnolence, impulse control disorders (gambling, hypersexuality), hallucinations
  • Monitoring: Screen for impulse control disorders regularly

MAO-B Inhibitors:

  • Options: Selegiline, rasagiline, safinamide
  • Use: Monotherapy in mild disease, adjunct to levodopa
  • Benefits: Mild symptomatic benefit, may have neuroprotective effect (unproven)
  • Side effects: Generally well-tolerated, insomnia with selegiline

COMT Inhibitors:

  • Options: Entacapone, opicapone, tolcapone
  • Use: Adjunct to levodopa, reduces wearing off
  • Benefits: Extends levodopa effect, reduces OFF time
  • Side effects: Diarrhea, urine discoloration, liver toxicity (tolcapone)

Amantadine:

  • Use: Antiviral with antiparkinsonian effects
  • Benefits: Reduces dyskinesias, mild symptomatic benefit
  • Side effects: Livedo reticularis, ankle edema, hallucinations

Advanced Therapies:

Deep Brain Stimulation (DBS):

  • Targets: Subthalamic nucleus (STN) or globus pallidus interna (GPi)
  • Indications: Motor fluctuations, dyskinesias, tremor, despite optimal medical therapy
  • Benefits: Reduces motor fluctuations, dyskinesias, improves quality of life
  • Candidates: less than 70 years, good cognition, levodopa responsive, no significant comorbidities
  • Risks: Surgical complications, hardware issues, infection

Levodopa-Carbidopa Intestinal Gel (LCIG):

  • Delivery: Continuous duodenal infusion via PEG tube
  • Indications: Severe motor fluctuations despite oral therapy
  • Benefits: Smooth levodopa delivery, reduces fluctuations
  • Limitations: Requires PEG tube, pump, expensive

Apomorphine:

  • Delivery: Subcutaneous injection or continuous infusion
  • Use: Rescue therapy for OFF episodes, continuous infusion for severe fluctuations
  • Benefits: Rapid onset, effective for OFF episodes
  • Side effects: Nausea, injection site reactions

Non-Motor Symptom Management:

Depression:

  • SSRI/SNRI: Sertraline, citalopram, venlafaxine
  • Pramipexole: May have antidepressant effect
  • Consider: Psychotherapy, ECT if severe

Cognitive Impairment:

  • Cholinesterase inhibitors: Donepezil, rivastigmine (if dementia)
  • Memantine: May help in advanced dementia
  • Screen: Regular cognitive assessment

Autonomic Dysfunction:

  • Orthostatic hypotension: Fludrocortisone, midodrine, compression stockings
  • Urinary: Anticholinergics (oxybutynin), but caution with cognition
  • Constipation: Laxatives, increased fiber, adequate hydration

Sleep Disorders:

  • REM sleep behavior disorder: Clonazepam, melatonin
  • Insomnia: Sleep hygiene, consider sedatives
  • Excessive daytime sleepiness: Modafinil, reduce sedating medications
9. Complications

PD causes progressive complications affecting motor function, cognition, and quality of life. Long-term levodopa therapy leads to motor complications.

Motor Complications:

Levodopa-Induced Dyskinesias:

  • Incidence: 40-50% after 5 years of levodopa
  • Types: Choreiform, dystonic, peak-dose or diphasic
  • Management: Reduce levodopa dose, add amantadine, consider DBS
  • Impact: Can be disabling, affects quality of life

Motor Fluctuations:

  • Wearing off: Gradual return of symptoms before next dose
  • ON-OFF: Sudden, unpredictable switches between ON and OFF
  • Delayed ON: Delayed response to levodopa
  • No ON: Failure to respond to levodopa
  • Management: Increase frequency, add COMT inhibitor, consider DBS or LCIG

Freezing:

  • Episodes: Inability to initiate movement
  • Triggers: Doorways, turning, stress
  • Management: Cueing strategies, levodopa optimization, consider DBS

Falls:

  • Risk: Increases with disease progression
  • Causes: Postural instability, freezing, orthostatic hypotension
  • Consequences: Fractures, head injury, fear of falling
  • Prevention: Exercise, balance training, environmental modifications

Non-Motor Complications:

Cognitive Impairment:

  • Mild cognitive impairment: 20-50% of patients
  • Dementia: 40-80% over disease course
  • Features: Executive dysfunction, visuospatial impairment, memory problems
  • Management: Cholinesterase inhibitors, supportive care

Psychiatric:

  • Depression: 40-50% prevalence
  • Anxiety: 30-40% prevalence
  • Psychosis: 20-40%, often medication-induced
  • Impulse control disorders: 5-15% with dopamine agonists

Autonomic:

  • Orthostatic hypotension: Common, can cause falls
  • Urinary: Frequency, urgency, incontinence
  • Constipation: Very common, may be severe
  • Sexual dysfunction: Common in both men and women

Other:

  • Sleep disorders: Insomnia, REM sleep behavior disorder, excessive daytime sleepiness
  • Pain: Musculoskeletal, neuropathic, dystonic
  • Fatigue: Common, disabling
  • Swallowing: Dysphagia in advanced disease, risk of aspiration
10. Prognosis

PD is progressive but variable in rate. Most patients maintain independence for many years. Prognosis depends on age, disease subtype, and access to care.

Disease Progression:

  • Variable: Some progress slowly over 20+ years, others more rapidly
  • Motor: Gradual worsening, levodopa remains effective but complications develop
  • Cognitive: 40-80% develop dementia, usually after 10+ years
  • Functional: Most maintain independence for 10-15 years

Survival:

  • Life expectancy: Reduced by 1-2 years compared to general population
  • Factors: Age, comorbidities, dementia, falls
  • Mortality: Usually from complications (pneumonia, falls) rather than PD itself

Quality of Life:

  • Early disease: Good with treatment
  • Moderate: Variable, depends on complications
  • Advanced: Significantly impaired, requires support
  • Factors: Motor complications, cognitive decline, depression

Factors Affecting Prognosis:

  • Age: Younger onset may progress more slowly
  • Subtype: Tremor-dominant has better prognosis than postural instability/gait difficulty
  • Treatment: Early, optimal treatment improves outcomes
  • Complications: Motor and non-motor complications worsen prognosis
  • Support: Multidisciplinary care improves quality of life
Key Evidence & Guidelines

Major Guidelines:

  • NICE Guidelines (NG71, 2017): Parkinson's disease in adults
  • AAN Practice Parameter (2006, 2011): Treatment of Parkinson's disease
  • MDS Evidence-Based Medicine Review (2018): Treatment recommendations
  • EFNS/MDS-ES Guidelines (2013): Management of Parkinson's disease

Landmark Clinical Trials:

  1. Levodopa Trials (1960s-1970s): Established levodopa efficacy

    • Dramatic improvement in motor symptoms
    • Remains most effective treatment
    • Long-term complications recognized
    • PMID: Various historical
  2. ELLDOPA Trial (2004): Early vs delayed levodopa

    • Early levodopa more effective
    • No evidence of neurotoxicity
    • Supports early treatment
    • PMID: 15097290
  3. EARLYSTIM Trial (2013): Early DBS

    • DBS superior to medical therapy in early motor complications
    • Improved quality of life
    • Supports earlier DBS consideration
    • PMID: 23406026
  4. CALM-PD Trial (2000): Levodopa vs pramipexole

    • Levodopa more effective for motor symptoms
    • Pramipexole causes fewer dyskinesias
    • Trade-off between efficacy and complications
    • PMID: 11094131
  5. ADAGIO Trial (2009): Rasagiline neuroprotection

    • No evidence of disease modification
    • Symptomatic benefit confirmed
    • PMID: 19812336

Meta-Analyses:

  • Levodopa: Most effective for motor symptoms (Deuschl, 2006)
  • Dopamine agonists: Effective but more side effects (Stowe, 2010)
  • DBS: Effective for motor complications (Deuschl, 2006)
  • COMT inhibitors: Reduce OFF time (Stowe, 2010)

Systematic Reviews:

  • PD treatment: Comprehensive review (Connolly, 2014)
  • Non-motor symptoms: Management strategies (Seppi, 2011)
  • DBS: Indications and outcomes (Deuschl, 2006)
12. Patient

"What is Parkinson's disease?" Parkinson's disease is a condition where certain nerve cells in your brain gradually stop working. These cells produce a chemical called dopamine that helps control movement. When dopamine levels drop, it causes problems with movement like shaking, stiffness, and slowness. It's a progressive condition, meaning it gets worse over time, but treatments can help manage symptoms for many years.

"What causes it?" We don't know exactly what causes Parkinson's in most people. It's likely a combination of genetic and environmental factors. In about 10-15% of cases, it runs in families. Most cases happen by chance. It's not caused by anything you did or didn't do.

"What symptoms will I notice?" The main symptoms are:

  • Tremor: Shaking, usually in your hands, that's worse when you're resting
  • Stiffness: Your muscles feel tight and rigid
  • Slowness: Movements become slow and smaller
  • Balance problems: Trouble with balance and falls (usually later in the disease)

You might also notice:

  • Loss of smell (often years before other symptoms)
  • Constipation
  • Depression or anxiety
  • Sleep problems
  • Small handwriting

"How is it diagnosed?" Your doctor will examine you and look for the characteristic signs. There's no specific test - the diagnosis is based on your symptoms and examination. Your doctor might do some scans or tests to rule out other conditions. Sometimes a trial of medication (levodopa) helps confirm the diagnosis if your symptoms improve.

"Is there a cure?" Unfortunately, there's no cure yet. However, there are very effective treatments that can:

  • Control your symptoms for many years
  • Help you stay active and independent
  • Improve your quality of life

Research is ongoing, and new treatments are being developed.

"How is it treated?" The main treatment is a medication called levodopa, which your brain converts to dopamine. It's very effective for movement problems. Other medications include:

  • Dopamine agonists (mimic dopamine)
  • MAO-B inhibitors (help dopamine last longer)
  • Medications to help with specific symptoms

Your doctor will work with you to find the best combination. As the disease progresses, you might need:

  • Adjustments to your medications
  • Physical therapy
  • Occupational therapy
  • Speech therapy
  • Sometimes surgery (deep brain stimulation)

"Will I become disabled?" Most people with Parkinson's stay active and independent for many years - often 10-15 years or more. The disease progresses slowly, and treatments help manage symptoms. Some people do eventually need more help, but many continue to work, drive, and enjoy life for a long time.

"What about the shaking?" Not everyone with Parkinson's has a tremor, and if you do, medications usually help control it. The tremor is often worse when you're resting and may improve when you're using your hands. It's usually not painful, but it can be bothersome. Treatments can significantly reduce it.

"Will I get dementia?" Some people with Parkinson's develop thinking and memory problems, but not everyone. It's more common in advanced disease, usually after many years. If it does happen, there are treatments that can help. Your doctor will monitor your thinking and memory over time.

"What can I do to help myself?"

  • Take your medications as prescribed
  • Stay active: Exercise is very important and can help with symptoms
  • Eat well: A balanced diet helps
  • Stay socially active: Don't isolate yourself
  • Learn about the condition: Knowledge helps you manage better
  • Join a support group: Connecting with others helps
  • Work with your healthcare team: Regular follow-ups are important

"What about work and driving?" Many people continue working for years after diagnosis. You may need accommodations, but many people manage well. For driving, you'll need to be honest with yourself and your doctor about your abilities. Your doctor can help assess if it's safe for you to drive.

"Is there hope?" Absolutely. While there's no cure, treatments have come a long way, and research continues. Many people with Parkinson's live full, active lives for many years. The key is working closely with your healthcare team, staying active, and taking your medications as prescribed. New treatments are being developed, and there's reason to be optimistic about the future.

13. References
  1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. PMID: 24756517

  2. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-622. PMID: 23406026

  3. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508. PMID: 15590953

  4. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf. 2010;33(2):147-161. PMID: 20082541

  5. National Institute for Health and Care Excellence. Parkinson's disease in adults. NICE guideline [NG71]. 2017. Available at: https://www.nice.org.uk/guidance/ng71

  6. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908. PMID: 16943402

  7. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278. PMID: 19812336

  8. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284(15):1931-1938. PMID: 11035889

  9. Angelopoulou E, Stanitsa E, Karpodini CC, et al. Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson's Disease: An Updated Review. Medicina (Kaunas). 2023;59(8):1454. PMID: 37629744

  10. Colucci F, Gozzi A, Antenucci P, et al. Opicapone in Parkinson's Disease on Levodopa-Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study. Mov Disord Clin Pract. 2025;12(11):2034-2042. PMID: 40662211

  11. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42-S80. PMID: 22021174

  12. Stowe R, Ives N, Clarke CE, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev. 2010;(6):CD006564. PMID: 20556764

  13. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013;20(1):5-15. PMID: 23279439

  14. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S2-S41. PMID: 22021173

  15. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-844. PMID: 18307261

  16. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology. 2007;69(17):1701-1711. PMID: 17954784

  17. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595. PMID: 20457959

  18. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. PMID: 26474316

  19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184. PMID: 1564476

  20. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. PMID: 25904081

Last updated: 2025-12-24

At a Glance

EvidenceHigh
Last Updated2025-12-24

Red Flags

  • Falls early in disease (PSP?)
  • Poor Levodopa response (MSA?)
  • Rapid progression
  • Symmetrical onset

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines